I agree with supradsw. I suppose and I hope that they hasn't yet finished to collect and analyse data. Since Raj & C in many occasions promised the market "something" about belinostat ptcl data within 2012, they have been compelled to announce "something" before Christmas holidays
We will see ORR together with safety data at the end of January.
Spectrum Pharmaceuticals Announces Achievement of Primary Endpoint in Belinostat Registrational Trial
Trial surpassed an objective response rate (ORR) of at least 20% in Relapsed/Refractory Peripheral T-Cell Lymphoma (PTCL) patients.
The primary efficacy endpoint was established under a Special Protocol Assessment agreement with the U.S. Food and Drug Administration.
The Company expects NDA filing by mid-2013, and an FDA decision in 2014.
The complete safety evaluation has been accepted for presentation at the T- Cell Lymphoma Forum to be held in San Francisco, Jan 24-26, 2013.